| Gastric Adenocarcinoma
Trazimera vs Lonsurf
Side-by-side clinical, coverage, and cost comparison for gastric adenocarcinoma.Deep comparison between: Trazimera vs Lonsurf with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLonsurf has a higher rate of injection site reactions vs Trazimera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lonsurf but not Trazimera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Trazimera
Lonsurf
At A Glance
IV infusion
Weekly or every 3 weeks
HER2/neu receptor antagonist
Oral
Twice daily, Days 1-5 and Days 8-12 of 28-day cycle
Nucleoside metabolic inhibitor
Indications
- Breast Carcinoma
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
- Metastasis from malignant neoplasm of colon and/or rectum
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
Dosing
Breast Carcinoma (adjuvant) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly for 12-18 weeks, then 6 mg/kg IV q3w to complete 52 weeks total; alternatively, 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV q3w for 52 weeks.
Breast Carcinoma (metastatic) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly IV until disease progression.
Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV over 30-90 min q3w until disease progression.
Metastasis from malignant neoplasm of colon and/or rectum, Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 35 mg/m2 (max 80 mg per dose) orally twice daily with food on Days 1-5 and Days 8-12 of each 28-day cycle, as single agent or in combination with bevacizumab, until disease progression or unacceptable toxicity.
Severe Renal Impairment (CLcr 15-29 mL/min) 20 mg/m2 orally twice daily with food on Days 1-5 and Days 8-12 of each 28-day cycle; reduce to 15 mg/m2 twice daily if 20 mg/m2 is not tolerated; permanently discontinue if 15 mg/m2 is not tolerated.
Contraindications
—
—
Adverse Reactions
Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia
Serious Cardiomyopathy, severe infusion reactions, pulmonary toxicity, embryo-fetal toxicity, exacerbation of chemotherapy-induced neutropenia
Postmarketing Infusion reaction, oligohydramnios or oligohydramnios sequence, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Most common (>=10%) Neutropenia, anemia, thrombocytopenia, fatigue, nausea, decreased appetite, diarrhea, vomiting, abdominal pain, pyrexia
Serious Severe myelosuppression (including febrile neutropenia), pulmonary emboli, interstitial lung disease (including fatal cases)
Pharmacology
Trastuzumab-qyyp is a HER2/neu receptor antagonist that inhibits proliferation of HER2-overexpressing human tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells compared with cells that do not overexpress HER2.
LONSURF combines trifluridine, a thymidine-based nucleoside analog that is incorporated into DNA to interfere with DNA synthesis and inhibit cell proliferation, and tipiracil, a thymidine phosphorylase inhibitor that increases trifluridine systemic exposure by blocking its primary metabolic pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Trazimera
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
Lonsurf
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Trazimera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lonsurf
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Trazimera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Lonsurf
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Trazimera Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Gastric Cancer: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TrazimeraView full Trazimera profile
LonsurfView full Lonsurf profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.